Aptamer News and Research

RSS

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

DNA ‘nanorobot’ effectively targets cancer leaving healthy cells untouched: Study

Researchers have developed ‘nano-sized’ probes built from DNA that can seek and destroy cancer cells, leaving healthy cells untouched. These ‘nanorobots’ release their drug payload only when they reach and identify their target and are believed to improve many treatments for disease.

20 Feb 2012

PolyTherics announces acquisition of WEP

PolyTherics Limited, a provider of solutions to biopharmaceutical companies for the improvement of protein and peptide based drugs, is pleased to announce the acquisition of Warwick Effect Polymers, a provider of specialty biopolymers for the modification of biological products.

20 Jan 2012

AmberGen, SomaLogic enter licensing agreement for photocleavable biotin reagent

SomaLogic, Inc. and AmberGen, Inc. announced today that they have entered into a licensing agreement whereby AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use of SomaLogic's SOMAscan technology platform.

30 Nov 2011

NIH awards $3.2M for development of highly efficient system of generating nucleic acid molecules

The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.

29 Nov 2011

Low-cost, portable technique can detect specific proteins in human blood

Blood tests are important diagnostic tools. They accurately tease-out vanishingly small concentrations of proteins and other molecules that help give a picture of overall health or signal the presence of specific diseases. Current testing procedures, however, are expensive and time-consuming, while sophisticated test equipment is bulky and difficult to transport.

2 Sep 2011

New fluorescent tool can track mysterious workings of cellular RNAs

The ability to tag proteins with a green fluorescent light to watch how they behave inside cells so revolutionized the understanding of protein biology that it earned the scientific teams who developed the technique Nobel Prizes in 2008.

30 Jul 2011

New preclinical data from Baxter's BAX 499 hemophilia study presented at ISTH

Baxter International Inc. announced today that new data from a series of studies on BAX 499, an investigational compound for potential subcutaneous hemophilia therapy, were presented this week during the 23rd annual congress of the International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan.

From Baxter International Inc. 27 Jul 2011

Scientists to reveal latest research breakthroughs at 'Chemistry and Health' conference

To mark the International Year of Chemistry, the 94th Canadian Chemistry Conference and Exhibition will take place at the Palais des congr-s de Montr-al from June 5 to 9, 2011. The gathering is the biggest ever annual event in Canada to focus on science and the practice of chemistry.

4 Jun 2011

Novel topically-applied molecular microbicide protects women against HIV infection

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.

17 May 2011

New study finds nitric oxide gas appears to affect source of sickle cell pain crises

Nitric oxide gas appears to directly impact the source of the classic, disabling pain crises of sickle cell disease, Georgia Health Sciences University researchers report.

10 May 2011

Seventeen projects granted access to PRACE Research Infrastructure's Tier-0 resources

On this second PRACE regular call, a new system, CURIE funded by GENCI and installed at CEA, Bruyères-Le-Châtel, France and designed by BULL, came into production adding capability to the PRACE Research Infrastructure (RI). CURIE is the second Tier-0 system in the PRACE RI after "JUGENE" (GCS at Jülich). The number of PRACE systems will continue to grow and provide more capacity and services to the European communities.

6 Apr 2011

Novel biomarker test accurately detects proteins secreted from asbestos-related tumors

Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

29 Mar 2011

World's first cancer stem cell-targeting chemical missile

Deakin University medical scientists have created the world's first cancer stem cell-targeting chemical missile, placing them a step closer to creating a medical 'smart bomb' that would seek out and eradicate the root of cancer cells.

18 Feb 2011

New England Biolabs adds OneTaq and OneTaq Hot Start DNA Polymerases to line of PCR reagents

New England Biolabs has expanded its line of PCR reagents to include OneTaq™ and OneTaq Hot Start DNA Polymerases. Optimized blends of Taq and Deep Vent® DNA Polymerases, these new products offer robust amplification across a wide range of templates, including routine, AT-rich and GC-rich amplicons.

From New England Biolabs 15 Feb 2011

New compound appears to prevent pain crises in sickle cell disease: GHSU

A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.

1 Feb 2011

New approach to biomarker detection for early lung cancer diagnosis

Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.

2 Dec 2010

Regado presents poster on REG3 at AHA Scientific Sessions meeting

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting.

18 Nov 2010

Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases

Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control agents, announced today that it has received funding from the United States government under the Qualifying Therapeutic Discovery Project (QTDP) grants program to advance the development of the company's three programs, REG1, REG2 and REG3.

4 Nov 2010